QIAGEN to Present At the JPMorgan 27th Annual Healthcare Conference

• Press Release
• Source: QIAGEN N.V.
• On 12:24 pm EST, Wednesday January 7, 2009

VENLO, The Netherlands, Jan. 7, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NasdaqGS:QGEN - News) (Frankfurt:QIA.F - News) today announced that it will present at the JPMorgan 27th Annual Healthcare Conference at 11:30 a.m. PT on Wednesday, January 14, 2009. The conference is being held at Westin St. Francis in San Francisco, California.

Related Quotes

Symbol	Price	Change
QGEN	22.17	+0.11

{"s" : "qgen,qia.f","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Peer M. Schatz, QIAGEN's Chief Executive Officer, will provide an overview of the company, discuss QIAGEN's business as well as recent developments and outline future opportunities. QIAGEN's presentation will be webcasted live for investors and available for replay for a period of three months following the conference. The presentation can be accessed in the Investor Relations section at the Company's web site at http://www.qiagen.com.

About QIAGEN:

QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 2,900 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com.

The QIAGEN N.V. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3692

Statements contained in this release that are not historical facts are forward-looking statements, including statements about our products, markets, strategy and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: management of growth and international operations (including currency fluctuations and logistics), variability of our operating results, commercial development of our markets (including applied testing, clinical and academic research, proteomics, women's health/HPV testing and molecular diagnostics), our relationships with customers, suppliers and strategic partners, competition, changes in technology, fluctuations in demand, regulatory requirements, identifying, developing and producing integrated products differentiated from our competitors' products, market acceptance of our products, and integration of acquired technologies and businesses. For further information, refer to our filings with the SEC, including our latest Form 20-F. Information in this release is as of the date of the release, and we undertake no duty to update this information unless required by law.

          QIAGEN N.V.
          Dr. Solveigh Mahler, Director Investor Relations
            +49 2103 29 11710
            solveigh.maehler@qiagen.com
          Albert F. Fleury, Director Corporate Finance 
           and Investor Relations North America
            +1 301 944 7028
            albert.fleury@qiagen.com